Transcriptional and translational markers of syncytialization and biochemical differentiation are significantly decreased by rotenone. by O’Llenecia S. Walker (8486163)

S5 Fig - by Meihui Chen (1670020)

Flow chart of the study procedures. by Kazuhiko Ikeuchi (9234268)

“…The median age was 45 (interquartile range [IQR], 38–50), 98.5% (67/68) were men, and 97.1% (66/68) had HIV. …”

Synthesis and Antiproliferative Activity of a New Series of Mono- and Bis(dimethylpyrazolyl)‑<i>s</i>‑triazine Derivatives Targeting EGFR/PI3K/AKT/mTOR Signaling Cascades by Ihab Shawish (13015516)

Subjects:

Synthesis and Antiproliferative Activity of a New Series of Mono- and Bis(dimethylpyrazolyl)‑<i>s</i>‑triazine Derivatives Targeting EGFR/PI3K/AKT/mTOR Signaling Cascades by Ihab Shawish (13015516)

Subjects:

Variable importance plot (mean decrease accuracy and mean decrease Gini). by Fernando Martinez-Taboada (8655132)

Endoscopic injection into the vocal fold muscle. by Ikuo Mikoshiba (9312007)

Subjects:

Does Mean Platelet Volume Decrease in the presence of Coronary Artery Fistula? by Isa Sincer (7234577)

“…Several studies have shown the association between mean platelet volume (MPV) and cardiovascular diseases. …”

Fig 5 - by Andrea R. Thurman (5286005)

Injection and evaluation of GFP-labelled DFATs in vocal fold muscle. by Ikuo Mikoshiba (9312007)

Subjects:

Effect of DFATs implantation on the inhibition of atrophy in the atrophic vocal fold muscle. by Ikuo Mikoshiba (9312007)

Subjects:

Assessment of cell proliferation within the vocal fold muscle following DFATs transplantation. by Ikuo Mikoshiba (9312007)

Subjects:

Effect of DFATs transplantation on collagen accumulation within the atrophic vocal fold muscle. by Ikuo Mikoshiba (9312007)

Subjects:

Analysis of apoptotic cells within the vocal fold muscle following DFATs transplantation. by Ikuo Mikoshiba (9312007)

Subjects:

Assessment of the viability of DFATs within the vocal fold muscle using GFP immunostaining. by Ikuo Mikoshiba (9312007)

Subjects:

6:2 Chlorinated Polyfluoroalkyl Ether Sulfonate (F-53B) Induces Aging and Parkinson’s Disease-like Disorders in <i>C. elegans</i> at Low Concentrations by Hui Li (32376)

“…After exposure to F-53B at 2, 10, and 50 ng/L, C. elegans showed an aging phenomenon as lipofuscin was significantly increased by 48.7–57.5% and locomotion, such as center point speed, was significantly decreased in all exposure groups. …”

6:2 Chlorinated Polyfluoroalkyl Ether Sulfonate (F-53B) Induces Aging and Parkinson’s Disease-like Disorders in <i>C. elegans</i> at Low Concentrations by Hui Li (32376)

“…After exposure to F-53B at 2, 10, and 50 ng/L, C. elegans showed an aging phenomenon as lipofuscin was significantly increased by 48.7–57.5% and locomotion, such as center point speed, was significantly decreased in all exposure groups. …”

6:2 Chlorinated Polyfluoroalkyl Ether Sulfonate (F-53B) Induces Aging and Parkinson’s Disease-like Disorders in <i>C. elegans</i> at Low Concentrations by Hui Li (32376)

“…After exposure to F-53B at 2, 10, and 50 ng/L, C. elegans showed an aging phenomenon as lipofuscin was significantly increased by 48.7–57.5% and locomotion, such as center point speed, was significantly decreased in all exposure groups. …”

6:2 Chlorinated Polyfluoroalkyl Ether Sulfonate (F-53B) Induces Aging and Parkinson’s Disease-like Disorders in <i>C. elegans</i> at Low Concentrations by Hui Li (32376)

“…After exposure to F-53B at 2, 10, and 50 ng/L, C. elegans showed an aging phenomenon as lipofuscin was significantly increased by 48.7–57.5% and locomotion, such as center point speed, was significantly decreased in all exposure groups. …”

Large state-wide variation (8.5-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2019 ^a indicates ≥1.50 SD (16.8) from the mean (31.0... by Luke R. Cavanah (19022435)